Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Table 2 The proportion of responders among MDDCT recipients at each time point post-MDDCT

Cytokine and comparison	Proportion of post-vaccination responders				Chi-Square (peptide stimulated vs unstimulated)
Cytokine and comparison	Peptide stimulated		Unstimulated		Chi-Square (peptide stimulated vs unstimulated)
Day 15 vs day 0	CD4⁺ T-cells	CD8⁺ T-cells	CD4⁺ T-cells	CD8⁺ T-cells	p < 0.00001
IL-2	8/10	6/10	3/10	2/10
TNF	5/10	9/10	5/10	3/10
IFN-γ	5/9	4/10	0/10	1/10
Day 30 vs day 0	CD4⁺ T-cells	CD8⁺ T-cells	CD4⁺ T-cells	CD8⁺ T-cells	p < 0.00001
IL-2	6/9	7/10	2/9	3/9
TNF	9/10	8/10	3/10	2/10
IFN-γ	8/10	4/10	2/10	2/10
Day 120 vs day 0	CD4⁺ T-cells	CD8⁺ T-cells	CD4⁺ T-cells	CD8⁺ T-cells	p < 0.017
IL-2	5/9	1/9	2/9	0/9
TNF	5/9	2 /9	2/9	3/8
IFN-γ	5/9	4/9	2/9	2/9

The data used to calculate responses are shown in Fig. 3 and Additional file 7: Fig. S7. For each condition/cytokine, a responder was defined by a ≥ 50% increase in the percentage of cytokine production as compared to baseline (i.e. day 0). Chi-square analysis was performed using pooled data of all cytokines and comparing the proportion of responders in peptide-stimulated cells vs unstimulated cells of the same individuals

ISSN: 1742-6405